Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
:KURA
KURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.41 - $23.48
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.17M
Market Cap
$465.15M
Enterprise Value$48.15M
Total Cash (Recent Filing)$10.99K
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 01, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding80,754,960
10 Day Avg. Volume1,001,550
30 Day Avg. Volume1,169,396
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.75
Price to Cash Flow (P/CF)0.60
P/FCF Ratio0.60
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$25.00Price Target Upside344.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsZiftomenib demonstrated 100% and 83% CR rates in NPM1-m and KMT2A-r patients, respectively, with a clean safety profile.
Financial PositionThe zifto franchise is fully funded in 1L AML (NPM1/KMT2A), and a cash position of $727.4MM, making Kura shares an attractive investment opportunity.
Regulatory ProgressKura announced the on-time submission of the NDA for zifto in r/r NPM1-m AML, reinforcing confidence in the team's ability to execute and the potential for revenues.
Bears Say
Competitive LandscapeManagement highlighted the data 'compares favorably to the competition,' indicating a ~25% CR/CRh rate alongside a best-in-class safety profile without QTc prolongation.
Market ConcernsShort Interest (% Float) 12.8%.
---
Ownership Overview
1.47% Insiders
11.16% Mutual Funds
1.52% Other Institutional Investors
71.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.41 and its highest was $23.48 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $465.15M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is May 01, 2025 which is in 22 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Feb 26, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.636 by $0.416.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.62.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 80,754,960 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went down -1.544%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
---
Kura Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (344.84% Upside)
$25.00 (344.84% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 845.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $179.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.47%
12-Months-Change
Fundamentals
Return on Equity
-42.91%
Trailing 12-Months
Asset Growth
131.81%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
---
KURA Company Deck
---
KURA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment, driven by significant advancements in clinical trials, regulatory progress, and a strong financial position, despite increased expenses and ongoing net losses.Read More>---
KURA Stock 12 Month Forecast
Average Price Target
$25.00
▲(344.84% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
17/43 ratings generated profit
1 Year Average Return
+17.51%
reiterated a buy rating 3 months ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 39.53% of your transactions generating a profit, with an average return of +17.51% per trade.
---